Chris Zhong, CFA

Startup GTM | Agentic & Physical AI, Fintech | Ex-VC, Ex-JPM

📍 United States🔄 Updated September 2026💼 8 investments📅 3 years investing🗓 Last invested Apr 2025
VC🌍 United States
8
Total investments
2
Early stage
3
Mid stage
1
Late stage
3y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2025
Virtue AI sets the standard for advanced AI security platforms. Built on decades of foundational and award-winning research in AI security, its AI-native architecture unifies automated red-teaming, real-time multimodal guardrails, and policy-driven governance for enterprise agents, models, and apps. Virtue AI safeguards every MCP, input, and output—spanning text, code, image, video, and audio—in over 100 languages, detecting risks in sub-10 ms. Deploy in minutes across cloud, on-prem, or SaaS environments, or integrate directly with tools like ChatGPT and VS Code. With Virtue AI as your authenticated third-party partner, enterprises achieve unified visibility and assurance throughout the AI lifecycle—driving innovation without slowing performance.
Investor
Nov 2024
Snorkel AI is the frontier AI data lab, helping teams build the data and environments behind high-performing frontier and agentic AI. We combine platform technology with research-driven data development to create datasets, benchmarks, evals, and custom solutions for real-world AI systems. Founded out of the Stanford AI Lab in 2019, Snorkel works with leading AI labs and enterprises to move from better data to better outcomes. Snorkel led the development of Senior SWE-Bench and launched Open Benchmarks Grants with a $3 million commitment to support open-source datasets, benchmarks, and evaluation research. Supported projects include Agents’ Last Exam, OSWorld 2.0, Terminal-Bench, Continual Learning Bench, and SlopCode Bench. Learn more at snorkel.ai or follow @SnorkelAI.
Investor
Aug 2024
Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, lets transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation
Investor
Jul 2024
Cohere is the leading security-first enterprise AI company. We build cutting-edge foundation models and end-to-end AI products designed to solve real-world business problems. We partner closely with companies to deliver seamless integration, full customization, and easy-to-use solutions for their workforce and customers. Our all-in-one platform offers enterprises the highest levels of data security, privacy and optionality to deploy across all major cloud providers, private cloud environments, or on-premises. HQ: 171 John Street, 2nd Floor, Toronto, ON M5T 1X3
Investor
Jun 2024
Frore Systems is a pioneer in advanced thermal technologies that unleash performance across data centers and edge devices. The company’s flagship solutions include LiquidJetTM, a multi-stage 3D short-loop jetchannel multi-stage liquid cooling coldplate for data centers delivering higher GPU performance, improved PUE and reduced TCO; LiquidJetTM Nexus, a light weight integrated coldplate system that integrates multiple LiquidJets and eliminates all hoses, connectors and manifolds enabling ½U compute trays and AirJet®, the world’s first solid-state active air-cooling chip used in consumer, industrial, and IoT markets delivering higher performance in ultra-compact, silent, light, dustproof and water-resistant edge devices. Frore Systems’ patented cooling technologies are integrated into products from major OEMs and system builders worldwide. Headquartered in Silicon Valley, with manufacturing operations in Taiwan, Frore Systems is redefining thermal architecture for the AI era.
Board Observer
Mar 2024
Noah Medical is building the future of medical robotics. Our next generation robotic platform targets early diagnosis and treatment of patients across multiple indications. Based in Silicon Valley and backed by well-known institutional investors, our incredibly talented team of 70+ engineers, innovators and industry leaders brings years of experience from the top healthcare companies in the world.
Investor & Board Observer
Oct 2023
Cowbell is the commercial insurance partner that makes brokers more successful by delivering coverage clients can actually understand and protection that strengthens their business. Cowbells mission is to make digital risks manageable, helping businesses understand, prevent, and recover with confidence. We believe that protection should create confidence, not complexity. We don’t add to the noise. We help you make sense of it. That is Cowbell—the Sound Approach to Risk.
mid stageInsurance
Investor
Oct 2023
Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.
Experience · 12 entries
All (12)
Investments (8)
Board (2)
2026
Interim Partnership Lead
Jan 2026
Alchedata builds the data infrastructure powering the next generation of AI. Founded by veterans with 40+ years of combined experience across AI data, multimodal pipelines, and enterprise-scale data operations, we deliver what generic data vendors cannot: domain-specific, multimodal data on a closed-loop platform with embedded evaluation and reinforcement learning (RL) to drive continuous model improvement. The engine behind this is NVEX — our proprietary agentic orchestration layer that integrates data generation, evaluation, and post-training workflows end-to-end, transforming raw data into model-ready intelligence at scale. Our global network now spans the United States, Japan, Korea, and key European markets, serving organizations in robotics, physical AI, scientific research, and agentic AI. Built for the models that matter.
2025
Investor
Apr 2025
Virtue AI sets the standard for advanced AI security platforms. Built on decades of foundational and award-winning research in AI security, its AI-native architecture unifies automated red-teaming, real-time multimodal guardrails, and policy-driven governance for enterprise agents, models, and apps. Virtue AI safeguards every MCP, input, and output—spanning text, code, image, video, and audio—in over 100 languages, detecting risks in sub-10 ms. Deploy in minutes across cloud, on-prem, or SaaS environments, or integrate directly with tools like ChatGPT and VS Code. With Virtue AI as your authenticated third-party partner, enterprises achieve unified visibility and assurance throughout the AI lifecycle—driving innovation without slowing performance.
2024
Investor
Nov 2024
Snorkel AI is the frontier AI data lab, helping teams build the data and environments behind high-performing frontier and agentic AI. We combine platform technology with research-driven data development to create datasets, benchmarks, evals, and custom solutions for real-world AI systems. Founded out of the Stanford AI Lab in 2019, Snorkel works with leading AI labs and enterprises to move from better data to better outcomes. Snorkel led the development of Senior SWE-Bench and launched Open Benchmarks Grants with a $3 million commitment to support open-source datasets, benchmarks, and evaluation research. Supported projects include Agents’ Last Exam, OSWorld 2.0, Terminal-Bench, Continual Learning Bench, and SlopCode Bench. Learn more at snorkel.ai or follow @SnorkelAI.
Investor
Aug 2024
Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, lets transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation
Investor
Jul 2024
Cohere is the leading security-first enterprise AI company. We build cutting-edge foundation models and end-to-end AI products designed to solve real-world business problems. We partner closely with companies to deliver seamless integration, full customization, and easy-to-use solutions for their workforce and customers. Our all-in-one platform offers enterprises the highest levels of data security, privacy and optionality to deploy across all major cloud providers, private cloud environments, or on-premises. HQ: 171 John Street, 2nd Floor, Toronto, ON M5T 1X3
Show all 12 entries ↓
Investment activity
2023–2025 · 8 investments
202322024520251
Recent (last 2 years)Earlier